Combination Study of SV-BR-1-GM in Combination With INCMGA00012 and Epacadostat
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label study of Study WRI-GEV-007, which evaluates SV-BR-1-GM in metastatic or
locally recurrent breast cancer patients, in combination with the PD-1 inhibitor INCMGA00012
and the IDO inhibitor epacadostat. Patients who with advanced breast cancer who have failed
prior therapies will be eligible to enroll in this study. The study will evaluate SV-BR-1-GM
in combination with INCMGA00012 and epacadostat. Treatment cycles will be every 3 weeks with
evaluations for tumor progression or response every 6-12 weeks.